Oshino Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 11-12-2024
- Paid Up Capital ₹ 1.92 M
as on 11-12-2024
- Company Age 24 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.22 Cr
as on 11-12-2024
- Revenue 2.65%
(FY 2023)
- Profit 11.37%
(FY 2023)
- Ebitda 8.30%
(FY 2023)
- Net Worth 44.03%
(FY 2023)
- Total Assets -9.96%
(FY 2023)
About Oshino Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.92 M.
The company currently has active open charges totaling ₹1.22 Cr.
Vishal Gupta and Savita Rani serve as directors at the Company.
- CIN/LLPIN
U24239DL2000PTC103818
- Company No.
103818
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Oshino Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishal Gupta  | Director | 01-Oct-2005 | Current |
| Savita Rani | Additional Director | 07-Jan-2010 | Current |
Financial Performance of Oshino Drugs.
Oshino Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.65% increase. The company also saw a substantial improvement in profitability, with a 11.37% increase in profit. The company's net worth Soared by an impressive increase of 44.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oshino Drugs?
Unlock access to Oshino Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 18 May 2024 | ₹2.63 M | Open |
Canara Bank Creation Date: 15 Sep 2018 | ₹1.00 M | Open |
Canara Bank Creation Date: 31 Jan 2014 | ₹0.57 M | Open |
How Many Employees Work at Oshino Drugs?
Oshino Drugs has a workforce of 1 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oshino Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oshino Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
